Rapt Therapeutics

Youtube Subscribe

Open: 14.14 Close: 13.93 Change: -0.21

The best way to get information about Rapt Therapeutics Stock: Use an AI.

Are looking for the most relevant information about Rapt Therapeutics? Investor spend a lot of time searching for information to make investment decisions in Rapt Therapeutics. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Rapt Therapeutics are: RAPT, Therapeutics, Cantor, Fitzgerald, estimate, report, issue, and the most common words in the summary are: inc, therapeutic, corp, group, holding, ltd, technology, . One of the sentences in the summary was: Cantor Fitzgerald also issued estimates for the company’s FY2024 earnings at …

Concept Map

Semantic Network

Stock Summary

RAPT Therapeutics, Inc. focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. Its lead inflammation drug candidate is.

Today's Summary

Cantor Fitzgerald cut their FY2023 EPS estimates for RAPT Therapeutics in a research report issued to clients and investors on Wednesday, November 15th. Cantor Fitzgerald also issued estimates for the company’s FY2024 earnings at ($4.12) and $3.02 per share. RAPT Therapeutics, Inc. to post fy2027 earnings of $8.42 per share, Capital One Financial Forecasts (NASDAQ:RAPT) Posted by Defense World Staff on Nov 20th, 2023. Capital One financial forecasts (nasdaq:rapt) - defense world. RAPT Therapeutics Inc. reports increased R&D expenses amid progress in clinical trials. Net loss widens in Q3 2023; Strong Cash Position to Support Operations through Mid-2025.

Today's News

Cantor Fitzgerald cut their FY2023 EPS estimates for RAPT Therapeutics in a research report issued to clients and investors on Wednesday, November 15th. Cantor Fitzgerald also issued estimates for the company’s FY2024 earnings at ($4.12) and $3.02 per share. RAPT Therapeutics, Inc. to post fy2027 earnings of $8.42 per share, Capital One Financial Forecasts (NASDAQ:RAPT) Posted by Defense World Staff on Nov 20th, 2023. Capital One financial forecasts (nasdaq:rapt) - defense world. RAPT Therapeutics Inc. reports increased R&D expenses amid progress in clinical trials. Net loss widens in Q3 2023; Strong Cash Position to Support Operations through Mid-2025.

Stock Profile

"RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California."

Keywords

How much time have you spent trying to decide whether investing in Rapt Therapeutics? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Rapt Therapeutics are: RAPT, Therapeutics, Cantor, Fitzgerald, estimate, report, issue, and the most common words in the summary are: inc, therapeutic, corp, group, holding, ltd, technology, . One of the sentences in the summary was: Cantor Fitzgerald also issued estimates for the company’s FY2024 earnings at ($4.12) and $3.02 per share. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #inc #therapeutic #corp #group #holding #ltd #technology.

Read more →

Youtube Subscribe

---